INNV - Profitability is key here. There are many,many companies that waste billions in some drug that might or might not work. In this company we have products that are being sold, bringing in revenue with significant growth trajectory. I think that part of the problem is that people still view this as the pharma company which will continue to dilute to fund research and operations. Reality is that they are very close to being cash flow positive. Their cash burn rate was $400k last quarter. Once they become profitable life will be so much easier as they can invest cash that they generate back into the business without issuing new shares. In theory they could issue shares but that will be mostly to acquire new companies and/or products. My overall point is that people will wake up and realize not only the potential but also realize that this company has a very different business model vs other pharma companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.